MedTrace Logo

Letrozole and Misoprostol for Early Pregnancy Loss Management

NCT06452719 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-05

No results posted yet for this study

Summary

A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.

Conditions

  • Early Pregnancy Loss
  • Miscarriage in First Trimester
  • Miscarriage

Interventions

DRUG

Letrozole

Letrozole 10 mg orally daily for three consecutive days

DRUG

Misoprostol

Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2026-07-15
Completion
2026-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06452719 on ClinicalTrials.gov